Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jul 26–Aug 2, 2026)
Here’s what’s on the biotech calendar for July 26–August 2: 1 FDA decision dates, 14 trial catalysts, and 1 earnings reports from tracked companies.
💊 FDA Decisions (PDUFA Dates)
| Date | Ticker | Drug | Indication | Type |
|---|---|---|---|---|
| 2026-07-29 | OTLK | — | Wet AMD <P STYLE=”font: 10pt Times New Roma | BLA |
🧪 Trial Catalysts & Milestones
- OSTX — 2026-07-30: Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Pro
- IBRX — 2026-07-31: PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
- OSTX — 2026-07-31: ProsTIC Registry of Men Treated With PSMA Theranostics
- CADL — 2026-08-01: A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadeno
- ACIU — 2026-08-01: A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune Sy
- IBO — 2026-08-01: A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Mod
- SSL — 2026-08-01: Artificial Intelligence (AI) Assisted Real-time Adenoma Detection and Classification Durin
- OSTX — 2026-08-01: Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiother
- OSTX — 2026-08-01: Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Ac
- GILD — 2026-08-01: Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
- CORT — 2026-08-01: Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecologic
- OSTX — 2026-08-01: Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin L
- OSTX — 2026-08-01: Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecologic
- GILD — 2026-08-01: A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemo
📊 Earnings This Week
- BIIB — 2026-07-29 (est. EPS 3.5792)
📡 Run-up Radar Highlights
Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):
- CAPR — BLA in 27 days, score 66/100
- ACRV — Phase 1 — Recruiting in 17 days, score 53/100
- OTLK — BLA in 3 days, score 53/100
📈 Last Week’s Biggest Gainers
- NVCR +28.39% (volume 5.2x average)
- AEHR +27.86% (volume 2.0x average)
- RNG +25.09% (volume 4.8x average)
- SMCI +19.84% (volume 3.2x average)
- ACHR +19.59% (volume 2.2x average)
Track your tickers on the BioRadar dashboard →
This digest is for informational purposes only and is not investment advice. Always do your own research.